Ignite Creation Date:
2024-07-17 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06463327
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-17
First Post:
2024-05-08
Brief Title:
ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia AML or Myelodysplastic Syndrome MDSAML
Sponsor:
TC Biopharm
Organization:
TC Biopharm
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-06
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-06
Completion Date Type:
ESTIMATED
First Submit Date:
2024-05-08
First Submit QC Date:
None
Study First Post Date:
2024-06-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-06-12
Last Update Post Date:
2024-06-17
Last Update Post Date Type:
ACTUAL